In addition to your trial experience of Windows Server 2022, you can more easily add and manage languages and Features on Demand with the new Languages and Optional Features ISO. Download this ISO.

Pfizer’s track record in tapping external innovation is also disappointing, Starboard alleged. Pfizer invested nearly $70 billion in M&A since 2022, as the pandemic was coming to an end.

Starboard’s presentation highlighted Pfizer’s failure to meet its ambitious targets, such as the plan for 15 potential blockbuster drugs by 2022, which Bourla had outlined when he took over as ...

At an investor summit in New York on Tuesday, activist investor Starboard called out Pfizer's PFE board of directors to take action against the latter’s management for making poor capital ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Activist investor Starboard Value has taken a sizeable stake in Kenvue Inc., the maker of Tylenol and Listerine, and is seeking changes, according to reports Sunday night. The Wall Street Journal ...

STARBOARD ULTRA 86L: 2025 TEST REVIEW THE VERDICT Providing some comfort when powered, the Ultra looks for a proactive rider who can provide and drive (…) ...

He also shared a version of the presentation his hedge fund Starboard presented to Pfizer officials at a meeting last week. "It's not often that investors and shareholders are able to see what we ...

Sales of the shot and Paxlovid, an antiviral drug Pfizer also developed, earned the company tens of billions of dollars in 2021 and 2022. But the company misjudged how durable demand for its shot ...

Investment firm Starboard Value, which has launched an activist ... has "significantly overpaid" for its acquisitions since 2022. Smith noted that Pfizer (NYSE:PFE) has lost $20B–$60B in market ...

It was first disclosed in October 2022 that Starboard had taken a "significant" stake in Salesforce (CRM) and that the ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has Johnson & Johnson’s consumer health spinout Kenvue in its sights.